Matteo Lambertini
Tumor Intrinsic Subtypes and Gene Expression Signatures in Early-Stage ERBB2/HER2-Positive Breast Cancer: A Pooled Analysis of CALGB 40601, NeoALTTO, and NSABP B-41 Trials.
Fernandez-Martinez A, Rediti M, Tang G, Pascual T, Hoadley K, Venet D, Rashid N, Spears P, Islam N, El-Abed S, Bliss J, Lambertini M, Di Cosimo S, Huober J, Goerlitz D, Hu R, Lucas P, Swain S, Sotiriou C, Perou C, Carey L. Tumor Intrinsic Subtypes and Gene Expression Signatures in Early-Stage ERBB2/HER2-Positive Breast Cancer: A Pooled Analysis of CALGB 40601, NeoALTTO, and NSABP B-41 Trials. JAMA Oncol 2024
Mar 28, 2024Tumor Intrinsic Subtypes and Gene Expression Signatures in Early-Stage ERBB2/HER2-Positive Breast Cancer: A Pooled Analysis of CALGB 40601, NeoALTTO, and NSABP B-41 Trials.
Mar 28, 2024JAMA Oncol 2024
Fernandez-Martinez Aranzazu, Rediti Mattia, Tang Gong, Pascual Tomás, Hoadley Katherine A, Venet David, Rashid Naim U, Spears Patricia A, Islam N, El-Abed Sarra, Bliss Judith, Lambertini Matteo, Di Cosimo Serena, Huober Jens, Goerlitz David, Hu Rong, Lucas Peter C, Swain Sandra M, Sotiriou Christos, Perou Charles M, Carey Lisa A
Pregnancies during and after trastuzumab and/or lapatinib in patients with human epidermal growth factor receptor 2-positive early breast cancer: Analysis from the NeoALTTO (BIG 1-06) and ALTTO (BIG 2-06) trials
Lambertini M, de Azambuja E, Gelber R, Piccart-Gebhart M, Moreno-Aspitia A, Baselga J, Huober J, Tenglin R, Di Cosimo S, Azim H, Korde L, Schuehly U, Hilbers F, Guillaume S, Campbell C, Martel S, Ignatiadis M. Pregnancies during and after trastuzumab and/or lapatinib in patients with human epidermal growth factor receptor 2-positive early breast cancer: Analysis from the NeoALTTO (BIG 1-06) and ALTTO (BIG 2-06) trials. Cancer 2018; 125:307-316.
Oct 18, 2018Pregnancies during and after trastuzumab and/or lapatinib in patients with human epidermal growth factor receptor 2-positive early breast cancer: Analysis from the NeoALTTO (BIG 1-06) and ALTTO (BIG 2-06) trials
Oct 18, 2018Cancer 2018; 125:307-316
Lambertini Matteo, de Azambuja Evandro, Gelber Richard D, Piccart-Gebhart Martine, Moreno-Aspitia Alvaro, Baselga José, Huober Jens, Tenglin Richard C, Di Cosimo Serena, Azim Hatem A, Korde Larissa, Schuehly Uwe, Hilbers Florentine S, Guillaume Sébastien, Campbell Christine, Martel Samuel, Ignatiadis Michail
Cardiac biomarkers for early detection and prediction of trastuzumab and/or lapatinib-induced cardiotoxicity in patients with HER2-positive early-stage breast cancer: a NeoALTTO sub-study (BIG 1-06)
Ponde N, Maetens M, Harbeck N, Pusztai L, Berghorn M, Im Y, Borrego M, Chen D, Rodeheffer R, Piccart M, Suter T, Bozovic-Spasojevic I, Fumagalli D, Bradbury I, Lambertini M, Ewer M, Campbell C, Ameels H, Zardavas D, Di Cosimo S, Baselga J, Huober J, Izquierdo M, de Azambuja E. Cardiac biomarkers for early detection and prediction of trastuzumab and/or lapatinib-induced cardiotoxicity in patients with HER2-positive early-stage breast cancer: a NeoALTTO sub-study (BIG 1-06). Breast Cancer Res Treat 2017; 168:631-638.
Dec 27, 2017Cardiac biomarkers for early detection and prediction of trastuzumab and/or lapatinib-induced cardiotoxicity in patients with HER2-positive early-stage breast cancer: a NeoALTTO sub-study (BIG 1-06)
Dec 27, 2017Breast Cancer Res Treat 2017; 168:631-638
Ponde Noam, Maetens Marion, Harbeck Nadia, Pusztai Lajos, Berghorn Michael, Im Young-Hyuck, Borrego Manuel Ruiz, Chen Dar-Ren, Rodeheffer Richard, Piccart Martine, Suter Thomas, Bozovic-Spasojevic Ivana, Fumagalli Debora, Bradbury Ian, Lambertini Matteo, Ewer Michael, Campbell Christine, Ameels Helene, Zardavas Dimitrios, Di Cosimo Serena, Baselga José, Huober Jens, Izquierdo Miguel, de Azambuja Evandro